Introduction
============

Asarum is derived from the dried root and rhizome of *Asarum heterotropoides* Fr. Schmidt var. *mandshuricum* (Maxim) Kitag., *Asarum sieboldii* Miq. var. *seoulense* Nakai. or *Asarum sieboldii* Miq. It is commonly applied in Traditional Chinese Medicine (TCM) due to its anesthetic and analgesic properties ([@b1-etm-0-0-8811]). In addition, it is applied in combination with other TCMs for the treatment of various ailments. Ginger and Asarum application by acupoint sticking therapy have been suggested to improve the clinical symptoms of bronchial asthma ([@b5-etm-0-0-8811]). However, the usage of asarum is generally not recommended due to its toxicity. Previous studies have detected a number of potentially toxic components in asarum, including safrole, methyl eugenol, aristolochic acids, asarone, 3,5-dimethoxytoluene and benzene derivatives ([@b6-etm-0-0-8811],[@b7-etm-0-0-8811]). These components are associated with toxicity in multiple organs, including the central nervous system ([@b8-etm-0-0-8811]), kidneys ([@b9-etm-0-0-8811]) and liver ([@b10-etm-0-0-8811]). In addition, Asarum is carcinogenic ([@b11-etm-0-0-8811]). In particular, aristolochic acids in asarum have been previously demonstrated to exhibit significant nephrotoxicity, in addition to mutagenic and carcinogenic effects ([@b12-etm-0-0-8811]). Safrole has been revealed to be associated with the pathogenesis of hepatocellular carcinoma and to lead to respiratory paralysis ([@b13-etm-0-0-8811],[@b14-etm-0-0-8811]).

A number of previous studies have investigated the mechanism of toxicity mediated by single components contained within naturally occurring medicinal compounds. Yang *et al* ([@b14-etm-0-0-8811]) indicated that safrole may inhibit cytochrome 450 enzymes and result in the production of reactive metabolites, in turn leading to the inhibition of enzyme activity and increasing the risk of hepatocellular carcinoma progression. In addition, Patel *et al* ([@b15-etm-0-0-8811]) demonstrated that cytotoxicity exerted by β-asarone was associated with lipid peroxidation and glutathione depletion in hepatocytes. However, since TCMs exhibit multi-component, multi-target and multi-pathway characteristics, further research is required to unravel the mechanism of toxicity exerted by a single component within TCM herbal formulations ([@b16-etm-0-0-8811]). In a previous study, genomics and transcriptomics analyses were performed to reveal the mechanisms of asarum-induced lung toxicity, which were potentially mediated through the adenosine monophosphate-activated protein kinase/NF-κB and Bcl2 pathways, in addition to proteins associated with inflammation, leading to an inflammatory reaction ([@b11-etm-0-0-8811]). However, the safety and efficacy of asarum for clinical use remain poorly understood, since the effect of asarum on the liver remains to be fully elucidated.

The liver is the largest organ that participates in drug metabolism, where it serves an important role in energy, lipid and amino acid metabolism ([@b17-etm-0-0-8811]). Following liver injury, gene expression and metabolite profiles become aberrantly altered. Transcriptomics analyses study the transcription of all genes in cells at a global level ([@b18-etm-0-0-8811],[@b19-etm-0-0-8811]), whereas metabolomics analyses examine the levels of metabolites in bodily fluids or tissues. Combination of these two analyses results in a large amount of data being generated regarding the overall changes in the metabolic spectrum, as a consequence of alterations in the transcriptome ([@b20-etm-0-0-8811],[@b21-etm-0-0-8811]). In the present study, to assess the underlying mechanism of the hepatotoxicity of asarum, transcriptomics and metabolomics datasets were generated and subsequently integrated to investigate prospective changes in the transcriptional and metabolic profiles of rats treated with asarum. Taken together, the present study aimed to provide novel insight into the mechanism of asarum-mediated toxicity, which may provide approaches to improve the clinical diagnosis and development of therapeutic interventions against asarum poisoning.

Materials and methods
=====================

### Chemicals and reagent kits

Alanine transaminase (ALT; cat. no. BQ004A-CR), aspartate transferase (AST; cat. no. BQ006A-CR) and total bilirubin (TBil; cat. no. BQ012A-CR) assay reagent kits were obtained from Rayto Life and Analytical Sciences Co., Ltd. TRIpure RNA extraction reagentwas obtained from BioTeke Corp. The Agilent Fiehn GC/MS Metabolomics Standards Kit was purchased from Agilent Technologies, Inc. N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA), chlorotrimethylsilane (TMCS) and methoxyamine hydrochloride were of gas chromatography (GC) derivatization grade and were purchased from Sigma-Aldrich; Merck KGaA. Other reagents used in the present study were of analytical grade.

### Quality control of asarum

Asarum (cat. no. 201809014) was obtained from Wuhan Hankou National Pharmaceutical Co., Ltd. The volatile components of asarum were analyzed using headspace-solid phase microextraction (HS-SPME) combined with GC-mass spectrometry (GC-MS). In brief, 0.3 g asarum powder was placed in a 20-ml HS vial to extract volatile components. The sample was heated for 15 min in a thermostatic bath at 90˚C for equilibration. The fiber was exposed to the HS for 15 min during the extraction time. Following sampling, the SPME fiber was immediately inserted into the GC injector and thermally desorbed for 3 min at 260˚C in 'split-less' mode. The relative percentage of each component was calculated using the area normalization method where the area of a single peak is divided by the total peak area.

### Animals

Previous experiments have demonstrated that 1.35 g asarum/kg/day induces lung toxicity in rats ([@b11-etm-0-0-8811]). Therefore, possible asarum-induced hepatotoxicity was evaluated at the same dose. Asarum root was first crushed using a pulverizer, following which double-distilled H~2~O was added to prepare a 13.5% suspension for intragastric administration.

In total, 40 male Sprague Dawley (SD) rats (weight, 200-230 g; age, 40-42 days) were purchased from the experimental animal research center of Hubei Province (license number, ZCXK, Hubei 2015-0018). Following one week of acclimatization at 18-25˚C and a relative humidity of 60-70%, with natural circadian rhythm and light. The rats had free access to food and water. The rats were divided into the following two groups (n=20): i) Control; and ii) asarum treatment. Subsequently, asarum (1.35 g/kg/day) was administered by oral gavage over a 28-day period, whilst the control group was administered equivalent volumes of saline. General parameters of each group of rats, including skin, hair and behavioral activities, were monitored daily throughout the duration of the experiment. Rats were used for H&E staining ([@b3-etm-0-0-8811]), metabolite testing ([@b14-etm-0-0-8811]) and for gene expression analysis ([@b3-etm-0-0-8811]). All experimental procedures were performed in accordance with the guidelines established by the animal ethics committee of Hubei University of TCM (Wuhan, China; approval no. HUCMS201903001).

### Measurement of organ coefficient and liver function

Following 28 days of intragastric administration, rats were first anesthetized with 10% chloral hydrate (300 mg/kg) by intraperitoneal injection. None of the animals exhibited any signs of peritonitis after the administration of 10% chloral hydrate. Subsequently, 1 ml blood was obtained from the abdominal aorta and the rats were sacrificed by cervical dislocation. After the confirmation of cardiac and respiratory arrest, in addition to the disappearance of nerve reflex, the liver was obtained from each rat. The liver tissues were then rinsed with normal saline, blotted with filter paper and weighed. The organ coefficient was calculated as the weight of the liver relative to 100 g of the rat\'s body weight. To obtain serum samples, whole blood was centrifuged at 1,006.2 x g for 15 min at 4˚C, following which the activities of ALT, AST and TBil were determined using a biochemical analyzer (Rayto Life and Analytical Sciences Co., Ltd.) according to the manufacturer\'s protocol.

### H&E staining

After the rats were sacrificed, liver samples (\~1.5x1.5x0.3 cm) were stored in 4% paraformaldehyde solution at 4˚C for 24 h, embedded in paraffin, sectioned at 4.5 µm, stained with H&E as previously described ([@b22-etm-0-0-8811]) and observed for histopathological changes using standard light microscopy. Histopathological scoring analysis was performed by a pathologist according to protocols previously described ([@b22-etm-0-0-8811]). Assessment was performed by calculating the sum of the following individual score grades: i) 0 (no findings); ii) 1 (mild); iii) 2 (moderate); and iv) 3 (severe) for each of the following six parameters: i) Cytoplasmic color fading; ii) vacuolization; iii) nuclear condensation; iv) nuclear fragmentation; v) nuclear fading; and vi) erythrocyte stasis.

### Gene expression analysis

In total, 3 liver tissues were selected randomly from each group for high-throughput sequencing. In brief, 0.1 g liver tissue samples were homogenized using 1 ml TRIzol^®^ according to the manufacturer\'s protocol to extract total RNA. The RNA was then checked for purity and stability by gel electrophoresis and the concentration was determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.). The mRNA with polyA structures in total RNA was then enriched using Oligo (dT) magnetic beads (Biomag Biotechnology Co., Ltd.; cat. no. BMDT1000; 4˚C and 2 min) and fragmented into 200-300 bp pieces by ion disruption using theVAHTS Universal Plus DNA Library Prep Kit For Illumina (Biomag Biotechnology Co., Ltd., ND617) following the manufacturer\'s protocol. Using RNA as a template, the first-strand complementary (c)DNA was synthesized using random hexamer primers and reverse transcription, and second-strand cDNA was synthesized using the first-strand cDNA as a template with the High-Capacity cDNA Reverse transcription kit (cat. no. 4368813; Thermo Fisher Scientific, Inc.), following the manufacturer\'s protocol. The synthesized cDNA was purified using Agencourt Ampurebeads (Beckman Coulter, Inc.). The purified cDNA was then prepared using a TruSeq DNA single indexes Set A kit (Illumina Inc.; cat. no. FC-121-2001) and amplified using TruSeq PE Cluster Kit (Illumina, Inc.; cat. no. PE-300-2001) to obtain a cDNA library. The total library concentrations were tested using the Agilent 2100 Bioanalyzer prior to being subjected to paired-end sequencing based on the Illumina HiSeq sequencing platform using next-generation sequencing. The raw sequencing data were first filtered by cutadapt (<https://cutadapt.readthedocs.io/en/stable/>), following which the filtered high-quality sequence was aligned to the reference genome of the rat. Based on the alignment results, the expression level of each gene was calculated, and the samples were analyzed further in terms of difference, enrichment and cluster analyses. Differentially expressed genes (DEGs) were screened out using the unpaired t-test with P\<0.05 as the threshold. The Gene Ontology (GO) platform (<http://www.geneontology.org/>) and panther version 14 were used to perform functional enrichment analysis of the DEGs ([@b23-etm-0-0-8811]). The Database for Annotation, Visualization, and Integrated Discovery (DAVID; version 6.8; <https://david.ncifcrf.gov/>) coupled with the Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/pathway.html>) was used to determine significant pathways associated with the DEGs ([@b24-etm-0-0-8811]). Pathways with P-value thresholds of \<0.05 were considered potential target pathways.

### Metabolomics data collection and analysis

After thawing the liver tissue samples at room temperature, 1 ml physiological saline was added to 0.2 g tissue to disrupt the cells, following which 250 µl acetonitrile was added to 100 µl liver homogenate for protein precipitation. This sample was then homogenized by ultrasound (40 kHz) in an ice bath for 15 min and centrifuged at 11,180 x g for 10 min at 4˚C to obtain a 200-µl supernatant. The supernatant was transferred to a sample vial and concentrated using a centrifugal concentrator (1,006.2 x g) at 35˚C for 2 h to evaporate the solvent. Oximation was performed at 30˚C for 90 min following the addition of 40 µl methoxyamine pyridine solution (40 mg/ml). Trimethylsilylation was subsequently performed at 37˚C for 60 min following the addition of 80 µl derivatization reagent (MSTFA/TMCS ratio, 100:1 v/v). Subsequently, 10 µl d27-myristic acid (0.75 mg/ml in n-hexane) was added as a reference compound. The derivatized sample was finally transferred to a 250-µl vial for GC-MS analysis.

A 7890B GC system (Agilent Technologies, Inc.), equipped with a 5977B series mass selective detector (Agilent Technologies, Inc.) and a DB-5ms capillary column (30 m x 0.25 mm x 0.25 µm; Agilent Technologies, Inc.) was used to analyze the derivatized liver samples. To achieve good separation, the oven temperature was programmed from 60 to 250˚C at 10˚C/min and subsequently held at 60 and 250˚C for 1 and 10 min, respectively. The injector, source and quadrupole temperatures were set to 250, 230 and 150˚C, respectively, whilst the detector voltage was 70.0 eV and the MS spectra were obtained in the mass to charge ratio (m/z) range of m/z=50.0-600.0. A positive ionization mode was used. The flow rate of the carrier gas, helium, was 1.1 ml/min and the solvent delay time was 5.9 min. The injection volume was 1 µl and the split ratio was 10:1. The helium was injected at room temperature and 80 psi.

GC-MS raw data acquisitions were performed using the Agilent Masshunter software (Qualitative Navigator B.08.00; Agilent Technologies, Inc.). Spectra deconvolution was performed using the Automated Mass Spectral Deconvolution and Identification System (AMDIS) tool (<http://www.amdis.net/>) from the National Institute of Standards and Technology (NIST) library. All spectra were normalized to total peak intensity. Metabolites with P-values \<0.05 and fold changes \>2.0 were considered biomarkers. All biomarkers were tentatively identified using the retention index, the NIST database (<http://webbook.nist.gov/chemistry/>) and the Agilent Fiehn GC/MS Metabolomics RTL Library ([@b25-etm-0-0-8811],[@b26-etm-0-0-8811]). Principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), relative intensity analysis and pathway analysis were performed using the MetaboAnalyst 4.0 online tool (<http://www.metaboanalyst.ca/>) ([@b27-etm-0-0-8811]). R2 represents the fit of the model, and Q2 represents the prediction rate of the model. The closer the values of R2 and Q2 are to 1, the better the model constructed.

### Integrated analysis

Cytoscape 3.6.1 (<https://js.cytoscape.org/>) is a software tool for the visual exploration of biomedical networks composed of metabolic, gene and other types of interactions ([@b28-etm-0-0-8811]). Specifically, Metscape 3 (<http://MetScape.ncibi.org>) is a Cytoscape plug-in that allows users to build and analyze networks of genes and compounds, identify enriched pathways from expression profiling data and visualize changes in metabolite data ([@b29-etm-0-0-8811]). The data obtained for differentially abundant metabolites and DEGs from rats in the control and asarum-treated groups were imported into Metscape to obtain a global understanding of gene and metabolic changes to assess the underlying mechanisms of hepatotoxicity.

### Statistical analysis

Measurement data, including the data of organ coefficient, liver function, the histopathology score, DEG analysis and metabolite analysis, were presented as the mean ± standard deviation. The unpaired t-test was performed for comparison of means between two groups using SPSS 21.0 software (IBM Corp.). In addition, a hypergeometric test was performed for pathway and GO analysis. P\<0.05 was considered to indicate statistical significance.

Results
=======

### Volatile components associated with toxicity in asarum

In total, 27 volatile components were detected from asarum ([Table I](#tI-etm-0-0-8811){ref-type="table"}). The major volatile compounds identified in asarum samples were safrole (17.759%), methyl eugenol (12.017%), 3,5-dimethoxytoluene (11.595%), myristyl ether (6.463%) and benzene derivatives. These volatile components may be associated with the toxicity of asarum.

### Increased organ coefficient and liver function in asarum-treated rats

In the third week following asarum administration, rats in the asarum group became languid, where the periphery of the eyes and auricles appeared cyanotic and the fur appeared messy and glossy. Organ coefficients and parameters of liver function, including ALT, AST and TBil, were significantly higher in the asarum-treated rats compared with those in the control group ([Table II](#tII-etm-0-0-8811){ref-type="table"}). In general, the organ coefficient and liver function were observed to be relatively consistent between animals under normal circumstances. However, in the present study, the increase in organ coefficient suggested that congestion, edema or hypertrophy of the liver occurred following asarum treatment. In addition, increases in TBil, AST and ALT suggested liver injury after asarum treatment.

### Liver histology following asarum treatment

The liver tissues obtained from the control group presented with normal cellularity and well-preserved hepatic lobule, hepatic sinusoid and central vein structures ([Fig. 1A](#f1-etm-0-0-8811){ref-type="fig"}). By contrast, the liver tissues from the asarum group presented with morphological tissue degeneration, including ballooning degeneration, loose cytoplasm and signs of necrosis ([Fig. 1B](#f1-etm-0-0-8811){ref-type="fig"}). As observed in [Fig. 1C](#f1-etm-0-0-8811){ref-type="fig"}, the histopathology score in the asarum group was significantly higher compared with that in the control group, strongly suggesting hepatotoxicity following asarum treatment.

### Transcriptomics analysis of DEGs following asarum treatment

The heatmap indicated significant changes in 434 genes in liver tissues following asarum treatment, including 214 upregulated and 220 downregulated genes ([Fig. 2](#f2-etm-0-0-8811){ref-type="fig"}). In addition, the KEGG biological pathway database was used to analyze the biological pathways of the DEGs. In total, 18 KEGG pathways were identified to be significantly enriched in the DEG analysis, including circadian rhythm, p53 signaling, metabolic pathways, steroid biosynthesis and bile secretion pathways ([Table III](#tIII-etm-0-0-8811){ref-type="table"}). GO analysis was subsequently performed and it was observed that the functional terms 'cellular process' and 'metabolic processes' accounted for the largest percentages in the protein analysis through evolutionary relationships (PATHER) GO-Slim Biological Process category ([Fig. 3A](#f3-etm-0-0-8811){ref-type="fig"}), 'binding' and 'catalytic activity' were the highest in the PATHER GO-Slim Molecular Function category ([Fig. 3B](#f3-etm-0-0-8811){ref-type="fig"}), 'cell' and 'organelle' occupied the largest proportion in the PATHER GO-Slim Cellular Component category ([Fig. 3C](#f3-etm-0-0-8811){ref-type="fig"}) and finally, 'hydrolase' and 'transcription factor' accounted for the highest percentage in the PATHER Protein Class ([Fig. 3D](#f3-etm-0-0-8811){ref-type="fig"}). The numbers provided by a GO slim are an annotation count not a gene product count, and so gene products may be present in more than one bin.

### Identification and analysis of metabolites following asarum treatment

The total ion chromatograms ([Fig. 4](#f4-etm-0-0-8811){ref-type="fig"}) demonstrated marked differences in the metabolite profiles between the control and asarum groups, which were greater using multivariate analysis methods. PCA is able to convert multiple indicators into a number of comprehensive indicators to analyze differences between groups, whereas PLS-DA is able to enhance the separation between groups. A distinct separation was observed in the PLS-DA ([Fig. 5A](#f5-etm-0-0-8811){ref-type="fig"}) and PCA score plots ([Fig. 5B](#f5-etm-0-0-8811){ref-type="fig"}) of the two groups, where the R2 and Q2 were indicated to be 0.91 and 0.81, respectively, suggesting that liver metabolism was altered following asarum treatment.

Relative intensity analysis is frequently used to investigate changes in the levels of biomarkers ([@b27-etm-0-0-8811]). In total, 14 metabolites were identified as biomarkers from liver homogenates ([Table IV](#tIV-etm-0-0-8811){ref-type="table"}). These 14 metabolites identified are represented by the peaks in [Fig. 4](#f4-etm-0-0-8811){ref-type="fig"}. Compared with the control group, the levels of L-alanine, taurine, phosphoglycolic acid, xylitol, D-sorbitol, L-lactic acid, myo-inositol and L-aspartic acid were markedly increased, whilst the levels of spermidine, L-methionine, maltotriose, trehalose, ribitol and L-proline were indicated to be markedly lower in the asarum group ([Fig. 6](#f6-etm-0-0-8811){ref-type="fig"}).

The profiles of the biomarkers were subsequently imported into the MetaboAnalyst online tool to explore possible metabolic pathways affected by asarum treatment. A total of six metabolic pathways were identified as important metabolic pathways, as listed in [Fig. 7](#f7-etm-0-0-8811){ref-type="fig"}. Therefore, these observations suggest that asarum treatment disrupted the composition of endogenous metabolites in rats, inducing disturbances in taurine, hypotaurine and amino acid metabolism.

### Integrated analysis of metabolomics and transcriptomics data

MetScape 3 may be used to visualize and interpret metabolomics and gene expression profiling data in an integrated metabolic network ([@b28-etm-0-0-8811],[@b30-etm-0-0-8811]). To investigate the correlation of metabolites and gene expression affected by asarum treatment, metabolite and gene expression profiles were imported into the Cytoscape for Metscape analysis. The metabolite-gene associated network was revealed to be mainly associated with 'bile acid biosynthesis' and 'amino acid metabolism' ([Fig. 8](#f8-etm-0-0-8811){ref-type="fig"}). The differentially expressed/abundant genes and metabolites associated with these pathways are presented in [Table V](#tV-etm-0-0-8811){ref-type="table"}. The results suggested that bile acid biosynthesis and amino acid metabolism may be the key processes associated with the mechanism of asarum-mediated hepatotoxicity. Because no metabolite changes were found in the p53 signaling pathway, they were not shown in the figure during the integrated analysis.

Discussion
==========

Toxicity studies are a vital integral component of TCM development ([@b31-etm-0-0-8811]). In the present study, the asarum group exhibited significantly enhanced organ coefficients and liver function compared with the control group. In addition, pathological liver tissue staining indicated significant liver damage following asarum treatment, further supporting the notion of asarum-induced hepatotoxicity. Transcriptomics and metabolomics techniques were subsequently performed to investigate the potential mechanism of asarum-mediated hepatotoxicity. The transcription profiles exhibited by liver tissues were first studied, where P53 signaling, metabolic pathways, steroid biosynthesis and bile secretion pathways were indicated to be the most relevant signaling pathways associated with asarum treatment. The metabolomic profiles of liver tissues from the control and asarum groups were next analyzed, which revealed that the associated metabolites are mainly members of the taurine, hypotaurine and amino acid metabolic pathways. The obtained transcriptomics and metabolomics datasets were next integrated and the data indicated that asarum-induced hepatotoxicity was mainly mediated through alterations of bile acid biosynthesis and amino acid metabolism.

Bile acids, synthesized from cholesterol in the liver, serve an important role in the regulation of energy, glucose and lipid metabolism ([@b32-etm-0-0-8811]). Cholesterol 7α-hydroxylase (CYP7A1) serves as the rate-limiting enzyme in the classical biogenic pathway of bile acid synthesis ([@b33-etm-0-0-8811]), the activity of which restricts the synthesis of bile acids in the body. By regulating CYP7A1 activity, the synthesis of bile acids may be steadily maintained. During bile acid secretion, bile acids may conjugate with either taurine or glycine, a process that lowers their pKa and increases their solubility, resulting in their secretion into the intestines with bile in a process that is catalyzed by bile salt sulfotransferase (SULT2A1) ([@b34-etm-0-0-8811]). In the present study, CYP7A1 and SULT2A1 were indicated to be markedly downregulated following asarum administration, whilst the level of taurine was markedly increased. In addition, the levels of TBil were increased, suggesting that the synthesis and secretion of bile acids were affected by asarum administration.

The liver is the principal organ of amino acid metabolism. Under physiological conditions, basal levels of amino acid metabolism are high due to the high abundance of associated enzymes. Consequently, liver damage frequently results in aberrant amino acid metabolism and eventually loss of liver function. Three amino acids function as important intermediates in energy metabolism ([@b35-etm-0-0-8811]): Alanine is involved in the alanine-glucose cycle in the body; aspartic acid serves as the bridge between amino acid and sugar metabolism, as it reacts with pyridoxal phosphates to form oxaloacetate in a reaction catalyzed by transaminases to produce sugar by gluconeogenesis, whilst proline is synthesized by the glutamate pathway. In addition, taurine may be synthesized from methionine. The covalent interaction between taurine and bile acid enhances the solubility of bile acid, facilitating the exclusion from extrahepatic cells and consequently reduction of bile acid levels in the liver ([@b36-etm-0-0-8811]). In the present study, it was indicated that the levels L-alanine and L-aspartic acid were markedly incrased following asarum administration, whilst those of L-proline and L-methionine were markedly reduced. This observation, together with the result that the activities of AST and ALT were also increased, further suggests that asarum treatment induced abnormalities in amino acid metabolism.

The transcriptomic pathway enrichment analysis of the present study also indicated that the activity of the P53 signaling pathway was increased by asarum treatment. P53 signaling may induce apoptosis through a number of different pathways in a manner that is highly dependent on the cell type and upstream signaling ([@b37-etm-0-0-8811]). This may be associated with the presence of carcinogenic chemicals, e.g. safrole in asarum. A recent study reported that P53 signaling promoted bile acid disposition and alleviated cholestastic syndrome ([@b38-etm-0-0-8811]). However, further study is required to validate the role of the P53 signaling pathway, in addition to the role of each individual component of asarum, on hepatotoxicity.

In conclusion, the present study demonstrated that asarum-induced hepatoxicity may be mediated through the disruption of the bile acid and amino acid metabolism, in addition to the P53 signaling pathway. These data may provide novel insight into the mechanism of the hepatotoxic effect of asarum, which may aid in the development of novel clinical diagnostic strategies and therapeutic interventions for asarum poisoning.
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![Asarum treatment-induced hepatotoxicity. Hematoxylin and eosin staining of pathological liver tissues isolated from rats in (A) the normal group and (B) the Asarum group (magnification, x200). Cell necrosis (yellow arrow) and ballooning degeneration (red arrow) were observed. (C) Quantified histopathological scores. Values are expressed as the mean ± standard deviation. ^\*^P\<0.05 vs. Control group.](etm-20-02-1359-g00){#f1-etm-0-0-8811}

![Heatmap of differentially expressed genes in each liver isolated from rats in the control and Asarum groups. Following asarum treatment, 434 genes were significantly altered in liver tissues, including 214 upregulated and 220 downregulated genes. The horizontal coordinate displays the groups and the vertical coordinate the genes. Red indicates upregulated and green downregulated genes. C, control; H, asarum.](etm-20-02-1359-g01){#f2-etm-0-0-8811}

![Gene Ontology analysis of differentially expressed genes associated with asarum treatment. (A) PATHER GO-Slim Biological Process category. (B) PATHER GO-Slim Molecular Function category. (C) PATHER GO-Slim Cellular Component category. (D) PATHER Protein Class. GO, gene ontology; PATHER, protein analysis through evolutionary relationships.](etm-20-02-1359-g02){#f3-etm-0-0-8811}

![Total ion chromatogram of metabolites obtained from liver tissues isolated from rats in the Control and Asarum groups. (A) Control group and (B) asarum treatment group. The x-axis displays the retention time and the y-axis the peak abundance.](etm-20-02-1359-g03){#f4-etm-0-0-8811}

![Metabolic profiling of liver tissues isolated from rats in the control and asarum groups. (A) PC analysis and (B) partial least squares-discriminant analysis score plots, which indicated a distinct separation between the control and asarum groups. C, control; H, asarum; PC, principal component.](etm-20-02-1359-g04){#f5-etm-0-0-8811}

![Comparison of relative intensities of biomarkers observed in the liver tissues isolated from rats in the control and asarum groups. Following asarum treatment, 14 metabolites were indicated to be significantly altered in liver tissues, including 8 upregulated and 6 downregulated metabolites. The y-axis displays the relative intensity and the x-axis the experimental groups. C, control; H, asarum. The upper and lower horizontal lines represent the maximum and minimum values, the upper and lower borders of the box represent the upper and lower quartiles, the bars represent the median, and the circles represent the outliers.](etm-20-02-1359-g05){#f6-etm-0-0-8811}

![Metabolite enrichment analysis as a result of asarum treatment in the liver, where six metabolic pathways were identified to be the most important metabolic pathways.](etm-20-02-1359-g06){#f7-etm-0-0-8811}

![Networks of the metabolites and genes were visualized using Metscape 3. The entries were obtained from an integrated analysis of the asarum-mediated hepatotoxicity mechanism by combining metabolomics and transcriptomics data. The metabolite-gene associated network was mainly associated with bile acid biosynthesis and amino acid metabolism. Hexagons indicate metabolites, circles represent genes, edges indicate the association between each node. Input genes are shown in dark blue, input metabolites are shown in dark red. Light colors indicate differentially expressed genes. CAD, carbamoyl-phosphate synthetase 2 aspartate transcarbamylase and dihydroorotase; DARS, aspartyl-tRNA synthetase; ASS1, argininosuccinate synthase 1; DARS2, aspartyl-tRNA synthetase 2; IL4I1, interleukin 4 induced 1; GAD2, glutamate decarboxylase 2; GAD1, glutamate decarboxylase 1; CSAD, cysteine sulfinic acid decarboxylase; GGT1, γ-glutamyltransferase 1; GGTL4, γ-glutamyltransferase light chain 2; GGT3, γ-glutamyl transpeptidase 3; GGTL3, γ-glutamyltransferase 7; GGTLA1, γ-glutamyltransferase 5; GGT2, γ-glutamyltransferase 2; BAAT, bile acid-CoA, amino acid N-acyltransferase; SLC27A2, solute carrier family 27 member 2; AGA, aspartylglucosaminidase; ACY3, aminoacylase 3; ADSSL1 adenylosuccinate synthase 1; ASNS, asparagine synthetase; ADSS, adenylosuccinate synthase 2; GOT2, glutamic-oxaloacetic transaminase 2; GOT1, glutamic-oxaloacetic transaminase 1; SULT2B1, sulfotransferase family 2B member 1; MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; MARS, methionyl-tRNA synthetase 1; MARS2, methionyl-tRNA synthetase 2; BHMT2, betaine-homocysteine S-methyltransferase 2; BHMT, betaine-homocysteine S-methyltransferase; MAT2B, methionine adenosyltransferase 2B; MAT2A, methionine adenosyltransferase 2A; MAT1A, methionine adenosyltransferase 1A; DNMT1, DNA methyltransferase 1; TRDMT1, tRNA aspartic acid methyltransferase 1; DNMT3B, DNA methyltransferase 3 β; DNMT3A, DNA methyltransferase 3; SMS, spermine synthase; SRM, spermidine synthase; SAT1, spermidine/spermine N1-acetyltransferase 1; SAT2, spermidine/spermine N1-acetyltransferase family member 2; PAOX, polyamine oxidase; DHPS, deoxyhypusine synthase; AOC2, amine oxidase copper containing 2; ABP1, actin-binding protein 1; AOC3, amine oxidase copper containing 3; KLK1, kallikrein 1; KLK2, kallikrein 2; AARS2, alanyl-tRNA synthetase 2; AARS, alanyl-tRNA synthetase; GPT2, glutamic-pyruvic transaminase 2; GPT, glutamic-pyruvic transaminase; AGXT, alanine-glyoxylate and serine-pyruvate aminotransferase; AGXT2, alanine-glyoxylate aminotransferase 2; LDHC, lactate dehydrogenase C; LDHAL6A, lactate dehydrogenase A like 6A; LDHAL6B, lactate dehydrogenase A like 6B; CYB5D1, cytochrome b5 domain containing 1; LDHB, lactate dehydrogenase B; LDHA, lactate dehydrogenase A; CTH, cystathionine γ-lyase; P4HA3, prolyl 4-hydroxylase subunit α3; P4HB, prolyl 4-hydroxylase subunit β; PARS2, prolyl-tRNA synthetase 2; EPRS, glutamyl-prolyl-tRNA synthetase 1; P4HA2, prolyl 4-hydroxylase subunit α2; P4HA1, prolyl 4-hydroxylase subunit α1; PYCRL, pyrroline-5-carboxylate reductase 3; PYCR2, pyrroline-5-carboxylate reductase 2; PYCR1, pyrroline-5-carboxylate reductase 1; LAP3, leucine aminopeptidase 3.](etm-20-02-1359-g07){#f8-etm-0-0-8811}

###### 

Volatile components identified in asarum by headspace-solid phase microextraction-gas chromatography-mass spectrometry.

  Peak number   Retention time (min)   Compound name                  Molecular formula   Molecular weight   Relative percentage (%)
  ------------- ---------------------- ------------------------------ ------------------- ------------------ -------------------------
  1             8.398                  2-Pinene                       C~10~H~16~          136.125            1.175
  2             9.175                  Camphene                       C~10~H~16~          136.125            0.404
  3             10.609                 β-Pinene                       C~10~H~16~          136.125            1.497
  4             11.008                 Myrcene                        C~10~H~16~          136.125            0.331
  5             12.119                 3-decene                       C~10~H~16~          136.125            5.583
  6             12.764                 4-isopropyltoluene             C~10~H~14~          134.110            1.544
  7             12.942                 D-decadiene                    C~10~H~16~          136.125            0.628
  8             13.097                 Eucalyptol                     C~10~H~18~O         154.136            1.605
  9             14.041                 Terpinene                      C~10~H~16~          136.125            0.870
  10            14.764                 Isobutene                      C~10~H~16~          136.125            0.537
  11            14.875                 Terpinolene                    C~10~H~16~          136.125            0.363
  12            16.886                 Eugenone                       C~10~H~14~O         150.105            6.896
  13            17.419                 2-nonanol                      C~10~H~18~O         154.136            1.337
  14            17.641                 4-nonenol                      C~10~H~18~O         154.136            0.723
  15            17.797                 Methyl isopropyl alcohol       C~10~H~14~O         150.105            0.239
  16            18.152                 4-allyl anisole                C~10~H~12~O         148.089            0.737
  17            18.374                 Cis-sterol                     C~10~H~16~O         152.120            0.401
  18            19.185                 2-isopropyl-5-methyl anisole   C~11~H~16~O         164.120            0.306
  19            20.696                 3,5-dimethoxytoluene           C~9~H~12~O~2~       152.084            11.595
  20            21.596                 Safrole                        C~10~H~10~O~2~      162.068            17.759
  21            24.307                 Methyl eugenol                 C~11~H~14~O~2~      178.099            12.017
  22            24.501                 3,4,5-trimethoxytoluene        C~10~H~14~O~3~      182.094            4.142
  23            26.907                 Myristyl ether                 C~11~H~12~O~3~      192.079            6.463
  24            27.918                 3,4-propiophenone              C~10~H~10~O~3~      178.063            0.970
  25            28.029                 Elemene                        C~12~H~16~O~3~      208.110            0.537
  26            30.262                 Carcinol                       C~10~H~10~O~4~      194.058            1.392
  27            31.128                 Patchouli alcohol              C~15~H~26~O         222.198            0.290

###### 

Organ coefficients and parameters of liver function.

  A, Organ coefficients (g/100 g; n=7)               
  -------------------------------------- ----------- --------------
  Liver                                  3.65±0.39   4.23±0.30^a^
  B, Liver function (n=5)                            
  Parameter                              Control     Asarum
  TBil                                   2.66±0.39   29.2±3.65^a^
  ALT                                    46.2±2.71   64.0±5.58^a^
  AST                                    40.0±9.87   77.2±16.8^a^

Values are expressed as the mean ± standard deviation of at least three independent experiments. ^a^P\<0.05 vs. control following unpaired t-test with Welch\'s correction. AST, aspartate transferase; TBil, total bilirubin; ALT, alanine transaminase.

###### 

Significantly enriched pathways based on KEGG pathway analysis.

  Pathway ID   Pathway                                         Upregulated_KO                Downregulated_KO                P-value
  ------------ ----------------------------------------------- ----------------------------- ------------------------------- -------------
  ko04710      Circadian rhythm                                ARNTl, NPAS2                  BHLHB2, NR1D1, PER2             1.92x10^-8^
  ko04115      p53 signaling pathway                           SESN1, CDKN1A, ZMAT3, GTSE1   SERPINE1, CCNE, CCND1           2.16x10^-4^
  ko04713      Circadian entrainment                           GRIA3, NOS1                   ADCY3, RYR1, PER2               7.01x10^-4^
  ko01100      Metabolic pathways                              ASNS, GALE, CTH, GK           AK1, GCK                        2.32x10^-3^
  ko00100      Steroid biosynthesis                            DHCR7                         SQLE, MESO1                     5.65x10^-3^
  ko00750      Vitamin B6 metabolism                           N/A                           SERC, PDXP                      1.06x10^-2^
  ko04976      Bile secretion                                  N/A                           CYP7A1, SULT2A1, HMGCR, ABCG5   1.13x10^-2^
  ko02010      ABC transporters                                ABCG9, ABCG3                  ABCA4, ABCG5                    1.16x10^-2^
  ko04978      Mineral absorption                              HEPH                          MT1_2, ATP1A                    1.27x10^-2^
  ko03320      PPAR signaling pathway                          SCD, PPARD, GK                FABP4                           2.12x10^-2^
  ko00660      C5-Branched dibasic acid metabolism             N/A                           IRG1                            2.34x10^-2^
  ko04970      Salivary secretion                              ATP2B, NOS1                   ATP1A, ADCY3                    4.16x10^-2^
  ko04972      Pancreatic secretion                            ATP2A, ATP2B                  ATP1A, ADCY3, CLCA2             4.29x10^-2^
  ko00260      Glycine, serine and threonine metabolism        CTH                           SERC, SERA                      4.45x10^-2^
  ko04724      Glutamatergic synapse                           GRIA3, PLD1_2                 ADCY3, SLC1A7                   4.48x10^-2^
  ko04020      Calcium signaling pathway                       ADORA2B, ATP2A                ADCY3, RYR1                     4.61x10^-2^
  ko00909      Sesquiterpenoid and triterpenoid biosynthesis   N/A                           SQLE                            4.62x10^-2^
  ko04212      Longevity-regulating pathway-worm               SCD                           MT1_2, MAP2K6                   4.64x10^-2^

KEGG, Kyoto Encyclopedia of Genes and Genomes; KO, KEGG identifier; ARNTl, aryl hydrocarbon receptor nuclear translocator like 1; NPAS2, neuronal PAS domain protein 2; BHLHB2, basic helix-loop-helix protein 2; NR1D1, nuclear receptor subfamily 1 group D member 1; PER2, period circadian regulator 2; SESN1, sestrin 1; CDKN1A, cyclin dependent kinase inhibitor 1A; ZMAT3, zinc finger matrin-type 3; GTSE1, G2 and S-phase expressed 1; SERPINE1, serpin family E member 1; CCNE, cyclin E; CCND1, cyclin D1; GRIA3, glutamate ionotropic receptor AMPA type subunit 3; NOS1, nitric oxide synthase 1; ADCY3, adenylate cyclase 3; RYR1, ryanodine receptor 1; ASNS, asparagine synthetase; GALE, UDP-galactose-4-epimerase; CTH, cystathionine γ-lyase; GK, glycerol kinase; AK1, adenylate kinase 1; GCK, glucokinase; DHCR7, 7-dehydrocholesterol reductase; SQLE, squalene epoxidase; MESO1, transcription factor 15; SERC, ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1; PDXP, pyridoxal phosphatase; CYP7A1, cytochrome P450 family 7 subfamily A member 1; SULT2A1, sulfotransferase family 2A member 1; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; ABCG5, ATP binding cassette subfamily G member 5; ABCG9, ABC-2 type transporter family protein; ABCG3, ATP binding cassette subfamily G member 3; ABCA4, ATP binding cassette subfamily A member 4; HEPH, hephaestin; MT1_2, metallothionein 1/2; ATP1A, sodium/potassium-transporting ATPase subunit α; SCD, stearoyl-CoA desaturase; PPARD, peroxisome proliferator activated receptor delta; FABP4, fatty acid binding protein 4; IRG1, aconitate decarboxylase 1; ATP2B, P-type Ca2+ transporter type 2B; ATP2A, P-type Ca2+ transporter type 2A; CLCA2, chloride channel accessory 2; SERA, selenate/chlorate reductase subunit α; PLD1_2, pyridoxal 4-dehydrogenase; SLC1A7, solute carrier family 1 member 7; ADORA2B, adenosine A2b receptor; MAP2K6, mitogen-activated protein kinase kinase 6.

###### 

Identification of potential biomarkers.

  No.   Retention time (min)   Metabolite             P-value       Fold change   Associated pathway
  ----- ---------------------- ---------------------- ------------- ------------- ---------------------------------------------
  1     8.0415                 L-lactic acid          2.40x10^-5^   6.128         Glycolysis
  2     8.7148                 L-alanine              3.75x10^-4^   2.832         Alanine, aspartate and glutamate metabolism
  3     9.8959                 L-proline              3.60x10^-3^   3.598         Arginine and proline metabolism
  4     13.2286                L-methionine           4.24x10^-3^   2.756         Cysteine and methionine metabolism
  5     13.3784                L-aspartic acid        4.04x10^-3^   5.324         Alanine, aspartate and glutamate metabolism
  6     15.4022                Phosphoglycolic acid   2.42x10^-3^   2.514         Glyoxylate and dicarboxylate metabolism
  7     15.5519                Taurine                8.68x10^-3^   2.406         Primary bile acid biosynthesis
  8     16.8073                Ribitol                3.00x10^-6^   7.887         Pentose and glucuronate interconversions
  9     16.8572                Xylitol                2.83x10^-4^   3.124         Pentose and glucuronate interconversions
  10    18.2734                D-sorbitol             8.15x10^-4^   2.376         Fructose and mannose metabolism
  11    20.6283                Myo-inositol           7.22x10^-3^   3.198         Galactose metabolism
  12    22.1431                Spermidine             1.03x10^-3^   3.054         Arginine and proline metabolism
  13    26.0201                Trehalose              4.26x10^-3^   12.26         Starch and sucrose metabolism
  14    30.6569                Maltotriose            5.95x10^-4^   33.94         Carbohydrate digestion and absorption

###### 

Metabolic pathways identified in the interactome network using the Cytoscape software 3.6.1, incorporating gene transcription and metabolite profiles.

  Metabolic pathways enriched within the interactome network   Differentially expressed genes                       Differentially expressed metabolites
  ------------------------------------------------------------ ---------------------------------------------------- ---------------------------------------
  Bile acid synthesis                                          CYP7A1, SULT2A1, HMGCR                               Taurine, L-aspartic acid
  Amino acid metabolism                                        ASNS, CTH, DNMT3B, SAT1                              L-alanine, S-lactic acid, spermidine,
                                                                                                                    L-methionine, L-proline
  p53 signaling pathway                                        SESN1, CDKN1A, ZMAT3, GTSE1, SERPINE1, CCNE, CCND1   None

CYP7A1, cholesterol 7α-hydroxylase; SULT2A1, bile salt sulfotransferase; HMCGR, 3-hydroxy-3-methylglutaryl-CoA reductase; ASNS, asparagine synthetase; CTH, cystathionine γ-lyase; DNMT3B, DNA methyltransferase 3 β; SAT1, spermidine/spermine N1-acetyltransferase 1; SESN1, sestrin 1; CDKN1A, cyclin dependent kinase inhibitor 1A; ZMAT3, zinc finger matrin-type 3; GTSE1, G2 and S-phase expressed 1; SERPINE1, serpin family E member 1; CCNE, cyclin E; CCND1, cyclin D1.

[^1]: *Abbreviations:* DEG, differentially expressed gene; TCM, Traditional Chinese Medicine
